CBG and CBGa Cannabinoids
Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects. British journal of pharmacology, 163(7), 1344-1364.
CBGA is produced from GPP and OA by the synthase “Aromatic Prenyltransferase” or AP.
This biochemistry takes place in the plastid, which is also where the MEP pathway produces GPP and terpenes.
GPP is a shared substrate for both cannabinoids and terpenes.
After CBGA is synthesized, it is transported out of the plastid in a “hyaline” glob (Mahlberg), into the apoplast (Gulck).
This is where the conversion of CBGA to subsequent cannabinoids takes place.
If CBGA is not converted into a subsequent cannabinoid, it will accumulate in the trichome.
Heat may cause it to convert to its neutral, active form, CBG.
Interaction with Cannabinoid Receptors
CBGA and CBG have been shown to interact with cannabinoid receptors that bind CBD and THC, modulating their effect.
Many anecdotal reports have shown that CBG has similar effects to CBD. Medical studies have shown that CBG is a “potent adrenoceptor agonist,” (Cascio et al 2010) and other studies have shown that CBG has antibiotic properties (Appendino et al 2008).
It is worth noting that all of the general side-chain cannabinoids have been shown to exhibit potent antimicrobial properties.
CBGA is the cannabinoid precursor
The biosynthesis pathway leads through (or can be restricted by) CBGA
Link to Lecture Slides: https://drive.google.com/file/d/1txUxTJ9Ho6Z3R4jH5jOYUHjQuzwO2GSm/view?usp=sharing
*Due to the description character limit the full work cited for “CBG and CBGa Cannabinoids” can be viewed at… https://drive.google.com/file/d/1wi6esQPT0U7bIZdU5zoJqSstbUTmMCwe/view?usp=sharing
View original source video by clicking here